RhumbLine Advisers
JBIO

RhumbLine Advisers’s Jade Biosciences JBIO Stock Holding History

RhumbLine Advisers’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$909K Buy
40,908
+357
+0.9% +$7.45K ﹤0.01% 2375
2026
Q1 		$570K Sell
40,551
-9,502
-19% -$138K ﹤0.01% 2531
2025
Q4 		$772K Buy
50,053
+7,269
+17% +$85.3K ﹤0.01% 2373
2025
Q3 		$369K Sell
42,784
-1,786
-4% -$14.6K ﹤0.01% 2880
2025
Q2 		$445K Buy
44,570
+43,920
+6,757% +$1.49M ﹤0.01% 2755
2025
Q1 		$57.1K Buy
650
+262
+68% +$23K ﹤0.01% 3540
2024
Q4 		$36K Buy
388
+9
+2% +$776 ﹤0.01% 3721
2024
Q3 		$27.7K Sell
379
-52
-12% -$3.35K ﹤0.01% 3772
2024
Q2 		$25K Buy
431
+13
+3% +$8.62K ﹤0.01% 3832
2024
Q1 		$432K Buy
418
+14
+3% +$10.7K ﹤0.01% 2756
2023
Q4 		$320K Buy
404
+4
+1% +$2.04K ﹤0.01% 2929
2023
Q3 		$190K Buy
400
+29
+8% +$15.7K ﹤0.01% 3187
2023
Q2 		$223K Sell
371
-52
-12% -$33.3K ﹤0.01% 3186
2023
Q1 		$298K Buy
423
+16
+4% +$13.3K ﹤0.01% 2617
2022
Q4 		$417K Buy
407
+3
+0.7% +$2.18K ﹤0.01% 2554
2022
Q3 		$234K Buy
404
+27
+7% +$18K ﹤0.01% 2838
2022
Q2 		$206K Buy
+377
New +$180K ﹤0.01% 2916

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RhumbLine Advisers's JBIO Position: Q2 2026 in Review

RhumbLine Advisers increased its Jade Biosciences (JBIO) stake by 0.88% in Q2 2026, buying an estimated $7.45K and bringing the position to 40,908 shares worth $909K. The position accounts for ﹤0.01% of the portfolio, ranked #2375.

RhumbLine Advisers first reported a position in JBIO in Q2 2022 and has held it in 17 quarters since. 154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • RhumbLine Advisers held 40,908 shares of Jade Biosciences worth $909K as of Q2 2026.
  • RhumbLine Advisers bought 357 Jade Biosciences shares in Q2 2026, an estimated $7.45K.
  • Jade Biosciences made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2375 holding.
  • RhumbLine Advisers first reported a position in Jade Biosciences in Q2 2022 and has held it in 17 quarters since.
  • 154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.